A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer is a serious condition and is one of the leading cause of cancer related
health problem. It is estimated that in 2016, 5,200 Canadians will be diagnosed with
pancreatic cancer, and approximately 20% (1 in 5) of patients will have localized cancer
(cancer that is limited to pancreas and there is no evidence of cancer in other parts of the
body). Localized cancer is earlier stage of disease and surgery to remove the cancer is
standard of care in this condition. However, recent scientific and clinical studies show that
using the chemotherapy medication before surgery can improve the overall survival in patents
with localized pancreatic cancer. One of these chemotherapy regimen is combination of
fluorouracil, oxaliplatin, irinotecan, leucovorin (FOLFIRINOX) that we are going to evaluate
its effect in this study.
Because of promising result of this combination in more advanced stage of pancreatic cancer,
this study is going to examine its efficiency in earlier stage of pancreatic cancer
(localized form). Total number of participant in this study will be 20 patients with
localized form of pancreatic cancer without any evidence of cancer in other parts of the
body.
Laboratory tests show that it works by slowing down the growth of cancer or may cause cancer
cells to die. It is hoped that by shrinking the tumor size, the surgeon will be able to
remove the cancer and improve the overall survival.
Procedures start with 2 weeks of comprehensive evaluation. Approximately 20 eligible
subjects, based on this study criteria, will receive 6 treatment of this regimen every 2
weeks. Once 6 treatments have been completed, comprehensive re-evaluation procedures will be
repeated, and subjects without disease progression or unacceptable toxicity will continue on
their treatment based on treating team decision (surgical intervention, radiation therapy or
continue FOLFIRINOX or different regimen). Patients then will follow with CT scan, blood test
and physical examination every 3 months.